Jan Rosier
Overview
Explore the profile of Jan Rosier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bukara K, Schueller L, Rosier J, Martens M, Daems T, Verheyden L, et al.
Eur J Pharm Biopharm
. 2016 Sep;
108:220-225.
PMID: 27648957
Formulating poorly water soluble drugs using ordered mesoporous silica materials is an emerging approach to tackle solubility-related bioavailability problems. The current study was conducted to assess the bioavailability-enhancing potential of...
2.
Bukara K, Schueller L, Rosier J, Daems T, Verheyden L, Eelen S, et al.
J Pharm Sci
. 2016 Jul;
105(8):2381-5.
PMID: 27364460
The present study aims to evaluate the in vitro and in vivo performance of ordered mesoporous silica (OMS) as a carrier for the poorly water-soluble compound fenofibrate. Fenofibrate was loaded...
3.
4.
Thommes M, Baert L, Rosier J
Pharm Dev Technol
. 2010 Aug;
16(6):645-50.
PMID: 20731537
Darunavir (TMC 114) is a protease inhibitor used in the therapy of HIV-1. The aim of this study was to formulate 800 mg of Darunavir in a single unit dosage...
5.
Van Gyseghem E, Baert L, Van Remoortere P, van t Klooster G, Rouan M, Voorspoels J, et al.
Eur J Pharm Sci
. 2010 Aug;
41(2):193-200.
PMID: 20685614
Various formulations for combination of the anti-HIV protease inhibitor darunavir (DRV) and TMC41629, a pharmacokinetic booster for DRV, were studied. TMC41629 (a BCS-IV compound) was formulated in capsules, as polyethylene...
6.
Visser M, Baert L, van t Klooster G, Schueller L, Geldof M, Vanwelkenhuysen I, et al.
Eur J Pharm Biopharm
. 2009 Oct;
74(2):233-8.
PMID: 19861163
TMC240 is a very poorly soluble and poorly permeating HIV protease inhibitor. In order to enhance its oral bioavailability, a fast dissolving inulin-based solid dispersion tablet was developed. During the...
7.
Van Gyseghem E, Stokbroekx S, Novoa de Armas H, Dickens J, Vanstockem M, Baert L, et al.
Eur J Pharm Sci
. 2009 Sep;
38(5):489-97.
PMID: 19782132
The interconversion of the ethanolate, hydrate and amorphous form of TMC114 ((3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl)-carbamic acid hexahydrofuro-[2,3-b]furan-3-yl ester) in open conditions was characterized. TMC114 hydrate and ethanolate form isostructural channel solvates. The crystal...
8.
Baert L, van t Klooster G, Dries W, Francois M, Wouters A, Basstanie E, et al.
Eur J Pharm Biopharm
. 2009 Mar;
72(3):502-8.
PMID: 19328850
Long-acting parenteral formulations of antiretrovirals could facilitate maintenance and prophylactic treatment in HIV. Using the poorly water- and oil-soluble non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) as base or hydrochloride...
9.
Thommes M, Baert L, van t Klooster G, Geldof M, Schueller L, Rosier J, et al.
Eur J Pharm Biopharm
. 2009 Mar;
72(3):614-20.
PMID: 19303929
The aim of this study was to produce pellet formulations containing a high drug load (80%) of the poorly soluble HIV-protease inhibitor darunavir, using wet extrusion/spheronization with kappa-carrageenan or microcrystalline...
10.
Van Gyseghem E, Pendela M, Baert L, Rosier J, van t Klooster G, De Man H, et al.
Eur J Pharm Biopharm
. 2008 Jul;
70(3):853-60.
PMID: 18657611
Powders for reconstitution of the next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 with low water solubility were developed by using a spray-dry technology. Their flexible dosing ability makes them suitable...